Eli Lilly: The GLP-1 Revolution and What It Means for Long-Term Investors
Discover how Eli Lilly's GLP-1 treatments are transforming diabetes care.
💡 Eli Lilly's GLP-1 drugs transform diabetes treatment, promising long-term growth.
The pharmaceutical industry has witnessed a seismic shift in recent years, with the emergence of GLP-1 receptor agonists as a game-changer in the treatment of type 2 diabetes and obesity. At the forefront of this revolution is Eli Lilly and Company, whose stock has been on a tear, driven by the remarkable success of its GLP-1 franchise. The company's flagship product, Mounjaro, has been a major catalyst for this surge, with sales exceeding expectations and cementing 's position as a leader in the rapidly evolving diabetes and obesity landscape.
As of May 2026, 's market capitalization has surpassed $500 billion, with the stock price having appreciated by over 50% in the past 12 months. This impressive run has been fueled by the company's ability to capitalize on the growing demand for GLP-1 therapies, which have been shown to not only improve glycemic control but also promote significant weight loss. The addressable market for these treatments is vast, with an estimated 460 million people worldwide living with diabetes, and is well-positioned to tap into this enormous opportunity. According to a recent report by Goldman Sachs, the global GLP-1 market is expected to reach $20 billion by 2028, with 's Mounjaro and Trulicity products poised to capture a significant share of this market.
The GLP-1 revolution has also had a profound impact on the competitive landscape of the pharmaceutical industry. Traditional players such as Novo Nordisk and Sanofi have been forced to adapt to the changing landscape, with 's Ozempic and 's Soliqua facing increased competition from 's Mounjaro. However, 's commitment to innovation and its robust pipeline of GLP-1 products have enabled the company to stay ahead of the curve. The company's recent announcement of positive top-line results from its SURMOUNT-1 trial, which demonstrated the efficacy and safety of Mounjaro in patients with obesity, has further reinforced its leadership position in the GLP-1 space.
From a financial perspective, 's GLP-1 franchise has been a major driver of the company's growth, with Mounjaro sales reaching $1.3 billion in the first quarter of 2026, exceeding analyst expectations. The company's revenue growth has been impressive, with a year-over-year increase of 15% in the first quarter, driven primarily by the strong performance of its diabetes and obesity products. 's operating margin has also expanded, reaching 25.4% in the first quarter, reflecting the company's ability to leverage its scale and efficiency to drive profitability. According to a recent note by Morgan Stanley, 's GLP-1 franchise is expected to contribute over 50% of the company's total revenue by 2028, underscoring the importance of this product class to the company's long-term growth prospects.
As continues to execute on its GLP-1 strategy, the company is also exploring new avenues for growth, including the development of novel GLP-1 products and combinations. The company's recent partnership with Biogen to develop a GLP-1-based therapy for neurodegenerative diseases is a testament to its commitment to innovation and its desire to expand its presence in new therapeutic areas. This partnership has the potential to unlock new revenue streams for , while also reinforcing its position as a leader in the GLP-1 space.
Despite the impressive performance of 's stock, some investors have raised concerns about the company's valuation, with the stock trading at a forward price-to-earnings ratio of over 30. However, given the company's strong growth prospects and its dominant position in the GLP-1 market, we believe that 's valuation is justified. The company's commitment to innovation, its robust pipeline, and its ability to execute on its strategic priorities all contribute to its attractiveness as a long-term investment opportunity. According to a recent survey by Bank of America, 75% of investors believe that 's GLP-1 franchise will continue to drive growth for the company over the next 5 years, underscoring the confidence that investors have in the company's ability to deliver long-term value.
Looking ahead, we expect to continue to drive growth and innovation in the GLP-1 space, with Mounjaro and Trulicity remaining key drivers of the company's revenue and profitability. The company's expanding pipeline of GLP-1 products and combinations, as well as its partnerships and collaborations, will also contribute to its long-term growth prospects. As the pharmaceutical industry continues to evolve, is well-positioned to navigate the changing landscape, with its GLP-1 franchise serving as a foundation for its future success. For long-term investors, remains an attractive investment opportunity, with its strong growth prospects, commitment to innovation, and dominant position in the GLP-1 market all contributing to its appeal. As such, we believe that will continue to be a major player in the pharmaceutical industry, with its GLP-1 franchise driving growth and innovation for years to come.